PRAMIPEXOLE DIHYDROCHLORIDE

Post-LOE

pramipexole dihydrochloride

PharmaIN

ANDAORALTABLET

Approved

Oct 2010

Lifecycle

Post-LOE

Competitive Pressure

30/100

Clinical Trials

Data completeness

5/8 — Partial

PRAMIPEXOLE DIHYDROCHLORIDE (pramipexole dihydrochloride) by PharmaIN is 12. Approved for parkinson's disease, moderate-to-severe primary restless legs syndrome (rls). First approved in 2010.

Drug data last refreshed 18h ago

See 1 job working on PRAMIPEXOLE DIHYDROCHLORIDE →

Mechanism of Action

12.1 Mechanism of Action Pramipexole is a non-ergot dopamine agonist with high relative in vitro specificity and full intrinsic activity at the D 2 subfamily of dopamine receptors, binding with higher affinity to D 3 than to D 2 or D 4 receptor subtypes. Parkinson's Disease The precise mechanism of…

Worked on PRAMIPEXOLE DIHYDROCHLORIDE at PharmaIN? Share your interview experience or compensation data (+7 days Pro)

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Clinical Trials (3)

NCT00893841Phase 2Completed

Bipolar Study of Seroquel XR With Pramipexole Dihydrochloride

Started Feb 2009

96 enrolled

Bipolar Depression

NCT01074463Phase 1Completed

Pramipexole Dihydrochloride 0.25 mg Tablets Under Non-Fasting Conditions

Started Feb 2005

24 enrolled

Healthy

NCT01074450Phase 1Completed

Pramipexole Dihydrochloride 0.25 mg Tablets Under Fasting Conditions